Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.67 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.67 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.67 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
| ▸ | GGH | Q92820 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310597 | 1.00 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14719913 | 0.87 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14310838 | 0.87 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14729416 | 0.87 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL6270974 | 0.85 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL1533825 | 0.85 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL4572551 | 0.85 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL14683450 | 0.84 | NOD1 (0.47) | FOLH1NAALAD2RIMKLAGNPATKDM4E | |
| SCHEMBL4813214 | 0.84 | KMT2A (0.49) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL6307131 | 0.83 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLAGNPATGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084700-A | Amino acid derivative and application thereof | 贵州医科大学 | 2024-05-28 | — | — | CN | disclosed |
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | FOLH1 1455/4885NAALAD2 643/4885RIMKLA 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.